Overview

AG-73305 Single Ascending Dose Cohort Study in DME

Status:
Not yet recruiting
Trial end date:
2023-10-15
Target enrollment:
Participant gender:
Summary
This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate 4 dosing cohorts of AG-73305 administered by intravitreal injection in patients with diabetic macular edema (DME).
Phase:
Phase 2
Details
Lead Sponsor:
Allgenesis Biotherapeutics Inc.
Collaborator:
Lexitas Pharma Services, Inc.